Akin Atmaca

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Scott Antonia, José A. López-Martín, Johanna C. Bendell et al. · The Lancet Oncology · 2016 · 1.3K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Matthew D. Hellmann, Margaret K. Callahan, Mark M. Awad et al. · Cancer Cell · 2018 · 894 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

Salah‐Eddin Al‐Batran, J. T. Hartmann, Stephan Probst et al. · Journal of Clinical Oncology · 2008 · 784 citations · Full text

Medicine, Oncology, Pharmacology +17

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

Neal Ready, Anna F. Farago, Filippo de Braud et al. · Journal of Thoracic Oncology · 2018 · 378 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +7

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

Neal Ready, Patrick A. Ott, Matthew D. Hellmann et al. · Journal of Thoracic Oncology · 2019 · 325 citations · Full text

Medicine, Oncology, Pharmacology +8